NDA 020615 · Mylan Institutional
Duraclon
Clonidine Hydrochloride · Injection
OrphanLast checked: Nov 21, 2026Latest source record: Aug 1, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Oct 2, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
276
54 Phase 3, 19 recruiting
FAERS reports
5,684
3,889 serious, 937 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
NOTE: Duraclon ® (epidural clonidine) is not recommended for obstetrical, post-partum, or peri-operative pain management. The risk of hemodynamic instability, especially hypotension and bradycardia, from epidural clonidine may be unacceptable in these patients. However, in a rare obstetrical, post-partum or peri-operative patient, potential benefits may outweigh the possible risks.
What it is approved for
From the label in effect Mar 17, 2021.
INDICATIONS AND USAGE Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ).
Mechanism: Mechanism of Action Epidurally administered clonidine produces dose-dependent analgesia not antagonized by opiate antagonists. The analgesia is limited to the body regions innervated by the spinal segments where analgesic concentrations of clonidine are present. Clonidine is thought to produce analgesia at presynaptic and postjunctional alpha-2-adrenoceptors in the spinal cord by preventing pain signal transmission to the brain.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 1996 Original approval · Type 3 - New Dosage Form Review
2 products under this application
- DURACLON · CLONIDINE HYDROCHLORIDE 1MG/10ML (0.1MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- DURACLON · CLONIDINE HYDROCHLORIDE 5MG/10ML (0.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Clonidine" as an intervention, any sponsor and status, largest first.
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- PeriOperative ISchemic Evaluation-2 TrialPivotal-lookingCompleted
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT01082874 · 10,010 participants · Start Jul 2010 · Primary completion Mar 2014
Drug: Active Clonidine; Placebo Clonidine and 2 more · For: Cardiovascular Disease
Sites: Cleveland, Ohio; Rosario, Argentina; Parkville, Australia · 23 sites in all
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- Resistant Hypertension Optimal TreatmentPivotal-lookingStatus unknown
Instituto do CoracaoGovernment (non-federal)
NCT01643434 · 2,000 participants (planned) · Start Aug 2012 · Primary completion Dec 2013
Drug: Spironolactone; Clonidine · For: Hypertension
Sites: São Paulo, Brazil
- Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)Pivotal-lookingCompleted
University of EdinburghAcademic, hospital or other
NCT03653832 · 1,404 participants · Start Dec 11, 2018 · Primary completion Dec 14, 2023
Drug: Dexmedetomidine; Clonidine and 1 more · For: Critical Illness
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Blackpool, United Kingdom · 38 sites in all
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS StudyPivotal-lookingCompleted
Heart Care FoundationAcademic, hospital or other
NCT00421863 · 1,111 participants · Start Feb 2005 · Primary completion Jan 2009
Drug: Triatec 10 mg; Triatec HCT 5 and 7 more · For: Hypertension
Sites: San Pietro Vernotico, Italy; Chiari, Italy; Trebisacce, Italy · 45 sites in all
- Dexmedetomidine or Clonidine Infusion for Prevention of Delirium After Open Heart SurgeryPivotal-lookingActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT05029050 · 900 participants (planned) · Start Jan 17, 2022 · Primary completion Jul 31, 2026
Drug: Dexmedetomidine; Clonidine and 1 more · For: Delirium; Cognitive Decline; Frailty
Sites: Bergen, Norway; Oslo, Norway; Tromsø, Norway · 5 sites in all
- Nephropathy In Type 2 Diabetes and Cardio-renal EventsPivotal-lookingCompleted
University of Campania Luigi VanvitelliAcademic, hospital or other
NCT00535925 · 850 participants · Start Oct 2005 · Primary completion Dec 2011
Drug: SoC therapy; irbesartan and 12 more · For: Diabetic Nephropathy
Sites: Naples, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypertension762
- headache711
- off label use658
- pain640
- fatigue634
- hypersensitivity549
- drug ineffective524
- nausea476
- infusion related reaction442
- hepatic enzyme increased436
- joint swelling426
- rash411
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 6 |
| 2006 | 13 |
| 2007 | 11 |
| 2008 | 30 |
| 2009 | 16 |
| 2010 | 66 |
| 2011 | 115 |
| 2012 | 102 |
| 2013 | 67 |
| 2014 | 72 |
| 2015 | 110 |
| 2016 | 117 |
| 2017 | 244 |
| 2018 | 236 |
| 2019 | 222 |
| 2020 | 261 |
| 2021 | 329 |
| 2022 | 618 |
| 2023 | 649 |
| 2024 | 894 |
| 2025 | 895 |
| 2026 | 608 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.
Bohn E, Goren K, Switzer L, et al. · Dev Med Child Neurol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Clonidine for smoking cessation.
Gourlay SG, Stead LF, Benowitz NL · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Buprenorphine for managing opioid withdrawal.
Gowing L, Ali R, White JM, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Postoperative analgesia by intravenous clonidine.
Bernard JM, Hommeril JL, Passuti N, et al. · Anesthesiology 1991 · Clinical Trial, Randomized Controlled Trial
- Clonidine in the treatment of hypertension.
Garrett BN, Kaplan NM · J Cardiovasc Pharmacol 1980 · Clinical Trial, Randomized Controlled Trial
- Clonidine blocks acute opiate-withdrawal symptoms.
Gold MS, Redmond DE, Kleber HD · Lancet 1978 · Clinical Trial, Randomized Controlled Trial
Sponsor: Mylan Institutional
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.